The startup develops targeted cancer therapeutics through advanced computational biology and drug discovery technologies, enabling precise identification of potential drug candidates. This approach addresses the challenge of inefficient cancer treatment development, facilitating faster and more effective therapies for clinicians and patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatment development faces challenges in efficiently identifying effective drug candidates, leading to delays in providing faster and more effective therapies for clinicians and patients. Many cancers remain difficult to treat, and existing therapies often have limited efficacy or significant side effects.
Solution
HOIST is a biopharmaceutical company focused on developing novel cancer therapeutics by leveraging advanced computational biology and drug discovery technologies. The company's approach centers on identifying innovative drug targets and developing corresponding therapeutic candidates. HOIST is developing a portfolio of drug candidates, including HM-001, a therapy that leverages the MA-T® system's anti-tumor effects for non-muscle invasive bladder cancer, and ALKBH3 inhibitors for solid tumors. In addition to its drug development programs, HOIST offers preclinical research services, including the creation of patient-derived xenograft (PDX) models to support drug discovery and development.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel cancer therapeutics, as well as researchers and clinicians in oncology looking for advanced preclinical models and innovative treatment options.
Features
- MA-T® System: An innovative oxidation control technology that generates active species to inactivate viruses and eliminate bacteria, applied to develop anti-cancer drugs.
- HM-001: A drug candidate that utilizes the MA-T® system for non-muscle invasive bladder cancer treatment, currently in Phase I/IIa clinical trials.
- ALKBH3 Inhibitors: Development of inhibitors targeting ALKBH3, an RNA demethylase enzyme, for cancer therapy, with demonstrated efficacy in animal models.
- PDC/PDX Models: Creation of patient-derived cell (PDC) and xenograft (PDX) models to improve the prediction of drug efficacy and toxicity.
- Epitranscriptomics: Targeting RNA methylation modifications for cancer treatment by developing ALKBH inhibitors.